Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.44 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | CFB | P00751 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21858616 | 0.93 | ALDH1A1 (0.49) | ALDH1A1HPGDTSHRSMN1; SMN2PIK3CD | |
| SCHEMBL18114152 | 0.93 | ALDH1A1 (0.49) | ALDH1A1HPGDTSHRSMN1; SMN2PIK3CD | |
| SCHEMBL4762312 | 0.91 | ALDH1A1 (0.47) | ALDH1A1HPGDTSHRSMN1; SMN2PIK3CD | |
| SCHEMBL21858733 | 0.89 | PIK3CD (0.52) | ALDH1A1HPGDTSHRSMN1; SMN2PIK3CD | |
| Hydrochloric Acid SCHEMBL20378314 | 0.86 | PIK3CD (0.43) | ALDH1A1HPGDTSHRSMN1; SMN2PIK3CD | |
| SCHEMBL26632556 | 0.84 | BTK (0.42) | ALDH1A1HPGDTSHRKDM4ENPC1 | |
| SCHEMBL18114129 | 0.82 | PIK3CD (0.47) | ALDH1A1HPGDTSHRSMN1; SMN2PIK3CD | |
| SCHEMBL21858596 | 0.82 | ALDH1A1 (0.45) | ALDH1A1HPGDTSHRSMN1; SMN2PIK3CD | |
| SCHEMBL4419714 | 0.80 | TSHR (0.41) | ALDH1A1HPGDTSHRSMN1; SMN2PIK3CD | |
| Hydrochloric Acid SCHEMBL21858794 | 0.78 | PIK3CD (0.40) | ALDH1A1HPGDTSHRSMN1; SMN2PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250236608-A1 | EGFR INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2025-07-24 | — | — | US | disclosed |
| EP-4578451-A2 | COMPOUNDS AND COMPOSITIONS AS SPPL2A INHIBITORS | Novartis AG (CH) | 2025-07-02 | — | — | EP | disclosed |
| EP-4214210-B1 | COMPOUNDS AND COMPOSITIONS AS SPPL2A INHIBITORS | NOVARTIS AG (CH) | 2025-04-09 | — | — | EP | disclosed |
| US-20230365571-A1 | COMPOUNDS AND COMPOSITIONS AS Sppl2a INHIBITORS | NOVARTIS AG (CH) | 2023-11-16 | — | — | US | disclosed |
| US-20230365571-A1 | COMPOUNDS AND COMPOSITIONS AS Sppl2a INHIBITORS | NOVARTIS AG (CH) | 2023-11-16 | — | — | US | disclosed |
| US-20230365571-A1 | COMPOUNDS AND COMPOSITIONS AS Sppl2a INHIBITORS | NOVARTIS AG (CH) | 2023-11-16 | — | — | US | disclosed |
| EP-3277678-B1 | COMPOSITIONS AND METHODS OF TARGETING MUTANT K-RAS | NANTBIO INC (US) | 2020-03-18 | — | — | EP | disclosed |
| US-20180086752-A1 | COMPOSITIONS AND METHODS OF TARGETING MUTANT K-RAS | NANTBIO, INC. | 2018-03-29 | — | — | US | disclosed |
| EP-3277678-A1 | COMPOSITIONS AND METHODS OF TARGETING MUTANT K-RAS | NantBioScience, Inc. (US) | 2018-02-07 | — | — | EP | disclosed |
| WO-2016169886-A1 | PESTICIDALLY ACTIVE POLYCYCLIC DERIVATIVES WITH SULFUR SUBSTITUTED FIVE-MEMBERED RING HETEROCYLES | SYNGENTA CROP PROTECTION AG (CH) | 2016-10-27 | — | — | WO | disclosed |
| WO-2016161361-A1 | COMPOSITIONS AND METHODS OF TARGETING MUTANT K-RAS | NANTBIOSCIENCE, INC. (US) | 2016-10-06 | — | — | WO | disclosed |
| US-6759412-B2 | FOR PRODUCING DRUGS USED FOR THERAPY OF CARDIOVASCULAR DISEASES, STABLE OR UNSTABLE ANGINA PECTORIS, CORONARY HEART DISEASE, PRINZMETAL ANGINA, ACUTE CORONARY SYNDROME, HEART FAILURE, MYOCARDIAL INFARCTION, STROKE, THROMBOSIS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365571-A1 | COMPOUNDS AND COMPOSITIONS AS Sppl2a INHIBITORS | SPPL2A, SPPL2B, BACE1 | ALDH1A1 3565/4885HPGD 2716/4885TSHR 4010/4885 |
| US-20180086752-A1 | COMPOSITIONS AND METHODS OF TARGETING MUTANT K-RAS | KRAS, NRAS, HRAS | ALDH1A1 4472/4885HPGD 2564/4885TSHR 4248/4885 |
| US-20250236608-A1 | EGFR INHIBITORS | EGFR, ERBB2, ERBB3 | ALDH1A1 2147/4885HPGD 3572/4885TSHR 976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.